ACELYRIN, INC. ( (SLRN) ) just unveiled an announcement.
On February 6, 2025, ACELYRIN, INC. and Alumis Inc. announced a definitive merger agreement under which ACELYRIN will become a wholly owned subsidiary of Alumis in an all-stock transaction. The merger, unanimously approved by the boards of both companies, is expected to create a late-stage clinical biopharma company focused on developing and commercializing transformative therapies for immune-mediated diseases. The merged entity will operate under the Alumis name with a pro forma cash position of approximately $737 million, providing financial flexibility for future developments. The transaction is anticipated to close in the second quarter of 2025, subject to customary approvals.
More about ACELYRIN, INC.
ACELYRIN, INC. is a late-stage clinical biopharmaceutical company focused on accelerating the development and delivery of transformative medicines in immunology. Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes for patients with immune-mediated diseases.
YTD Price Performance: -41.21%
Average Trading Volume: 1,022,820
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $194.6M
Learn more about SLRN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com